Format

Send to

Choose Destination
Cardiovasc Ther. 2016 Aug;34(4):216-24. doi: 10.1111/1755-5922.12189.

Spironolactone Attenuates Doxorubicin-induced Cardiotoxicity in Rats.

Author information

1
Department of Cardiology, The First Affiliated Hospital of Harbin Medical University, Harbin, China.
2
Heihongjiang University of Chinese Medicine, Harbin, China.
3
Department of Biotechnology, School of Life Science, Jilin Normal University, Siping, China.

Abstract

INTRODUCTION:

In this study, we examined whether spironolactone (SP) could inhibit doxorubicin (DOX)-induced cardiotoxicity in the rat heart.

METHODS:

Rats were randomized into four groups (n = 6): (1) the control group; (2) the SP group; (3) the DOX group; and (4) the SP + DOX group. The rats were evaluated for electrocardiography and cardiac function. The cardiac collagen, cardiomyocyte apoptosis, and the remodeling-related proteins were determined.

RESULTS:

Rats treated with DOX showed prolongation of QTc and decreased left ventricular ejection fraction (EF) and fractional shortening (FS) (P < 0.05) showed left ventricular end-diastolic dimensions (LVEDD) and left ventricular end-systolic dimensions (LVESD) were significantly increased (P < 0.05). SP prevented these pathophysiological alterations (P < 0.05). In DOX-treated group, cardiac fibrosis, apoptotic cell number, and cardiac collagen volume fraction were higher than control group (P < 0.05); these effects were prevented by cotreatment of SP (P < 0.05). Moreover, the expressions of TGF-β1 and phosphorylated-Smad3 were increased after DOX treatment (P < 0.05) and significantly reduced by coadministration of SP (P < 0.05).

CONCLUSIONS:

This study show that SP may have a protective effect on DOX-induced cardiotoxicity.

KEYWORDS:

Cardiotoxicity; Doxorubicin; Smad3; Spironolactone; TGF-β1

PMID:
27097055
DOI:
10.1111/1755-5922.12189
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center